Black Hawk Acquisition CORP 10-Q quarterly reports

Black Hawk Acquisition Corporation files its Q2 2026 10-Q, detailing its ongoing business combination efforts with Vesicor Therapeutics and addressing Nasdaq listing concerns.

Black Hawk Acquisition Corporation has entered a definitive agreement to merge with biotech firm Vesicor Therapeutics, valuing it at $70 million, but faces significant shareholder redemptions and going concern doubts.

Black Hawk Acquisition Corporation, a SPAC, announced its second-quarter 2025 financial results, highlighted by increased net income and progress on its proposed business combination with Vesicor Therapeutics, Inc., while simultaneously disclosing substantial doubt about its ability to continue as a going concern and seeking an extension for its business combination deadline.

Black Hawk Acquisition Corporation reports a net income of $658,379 for the quarter ended February 28, 2025, driven by interest income from investments held in trust.

Black Hawk Acquisition Corporation reported a net income of $883,767 for the third quarter of 2024, primarily driven by interest income from its trust account.

Black Hawk Acquisition Corporation reported a net income of $280,235 for the six months ended May 31, 2024, primarily driven by interest income from its trust account.

Black Hawk Acquisition Corporation's first quarter 2024 report reveals a net loss of $30,701 and highlights substantial doubt about the company's ability to continue as a going concern.